SCHEMBL6163360

SCHEMBL6163360

CN(C)c1cc(NC(=O)OC(C)(C)C)c(N)cc1-c1cccc(F)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 7/20 0.37
RXFP1 Q9HBX9 1/20 0.36
CHRM3 P20309 3/20 0.36
KCNQ4 P56696 1/20 0.36
KCNQ5 Q9NR82 1/20 0.36
CYP17A1 P05093 1/20 0.35
SYK P43405 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
HDAC3 O15379 2/20 0.34
DYRK3 O43781 1/20 0.34
CDK1 P06493 1/20 0.34
CDK2 P24941 1/20 0.34
CLK2 P49760 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
CDK5 Q00535 1/20 0.34
PRKCD Q05655 1/20 0.34
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562894 0.91 RXFP1 (0.38) AAK1RXFP1CHRM3KCNQ4KCNQ5
SCHEMBL6609128 0.84 DYRK1A (0.37) CHRM3GPBAR1DYRK3CDK1CDK2
SCHEMBL6164705 0.84 RAB9A (0.37) RXFP1CHRM3KCNQ4KCNQ5
SCHEMBL6164977 0.81 AAK1 (0.38) AAK1RXFP1KCNQ4KCNQ5CYP17A1
SCHEMBL5869067 0.81 AAK1 (0.45) AAK1RXFP1KCNQ4KCNQ5CYP17A1
SCHEMBL6162569 0.76 EGLN2 (0.35) CHRM3KCNQ4KCNQ5HDAC3GSK3B
SCHEMBL6165321 0.75 AAK1 (0.37) AAK1RXFP1
SCHEMBL5562862 0.75 RAB9A (0.41) RXFP1
SCHEMBL7144127 0.75 RXFP1 (0.38) AAK1RXFP1CHRM3CYP17A1HSP90AA1
SCHEMBL7143058 0.75 AAK1 (0.44) AAK1RXFP1CHRM3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 AAK1 2640/4885RXFP1 421/4885CHRM3 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.